Technology
Genomics Market to Reach $70.52 Billion by 2031, Driven by Increasing Incorporation of Genomic Data in Clinical Workflows and Increasing Funding and Investments in Genomics Projects – Exclusive Report by Meticulous Research®
Published
2 years agoon
By
REDDING, Calif., Sept. 24, 2024 /PRNewswire/ — According to a new market research report titled, ‘Genomics Market Size, Share, Forecast, & Trends Analysis by Technology (Sequencing, Microarray, Nucleic Acid Extraction), Application (Drug Discovery, Diagnostic, Research), Offering (Instrument, Consumables, Software), End User—Global Forecast to 2031.
The genomics market is projected to reach $70.52 billion by 2031, at a CAGR of 11.1% from 2024 to 2031.
Download FREE PDF Brochure Of Genomics Market –
https://www.meticulousresearch.com/download-sample-report/cp_id=1262
The rising prevalence of genetic diseases, the increasing incorporation of genomic data in clinical workflows, increasing funding and investments in genomics projects, growing applications of genomics in the healthcare sector, rising pharmaceutical R&D expenditures, and increasing healthcare spending are key factors driving the growth of the genomics market. However, concerns over the security & privacy of genomic data and the lack of standardized approaches in genomics are factors restraining the growth of this market.
Furthermore, the rising adoption of personalized medicines and gene therapies is expected to create opportunities for the players operating in the genomics market. However, the shortage of skilled bioinformatics & genomics personnel and the commercialization & scaling of genomic technologies are major challenges impacting market growth. READ MORE
Increasing Funding and Investments in Genomics Projects Reshaping the Market Landscape
Pharmaceutical and biotechnology companies have been increasingly focused on genomic research since 2003 – the year of completion and publishing of the full sequence of the entire human genome. Furthermore, increasing funding for genomic research, the development of advanced sequencing technologies & bioinformatics tools, and the reducing costs of genomic studies are generating opportunities for pharmaceutical and biotechnology companies to engage more in the research and development of personalized/precision medicine, targeted therapeutics, and vaccines. These factors have also helped companies as well as academic & research institutes to conduct more studies focused on mapping and identifying variants and studying the mechanisms of various rare and genetic diseases.
Get Insightful Data On Regions, Market Segments, Customer Landscape, And Top Companies (Charts, Tables, Figures And More) – https://www.meticulousresearch.com/request-sample-report/cp_id=1262
The pharmaceutical industry is also investing in genomic data-sharing initiatives to accelerate the research and development of novel personalized therapies. Also, research and academic institutes are partaking in genomic studies and collaborating with key pharmaceutical companies to exchange genomic data and discover new personalized therapies for various rare and genetic diseases. Some of the recent funding and investments supporting genomics studies are as follows:
In December 2022, the U.K. government announced $217 million (€175 million) in funding for genomics research, including $130 million (€105 million) to boost the diagnosis of rare genetic diseases in newborns.In September 2022, the Centers for Disease Control and Prevention (CDC) announced $90 million in funding over the next five years to support the Pathogen Genomics Centers of Excellence (PGCoE) network, which is aimed at accelerating innovations and improving technical capacities in molecular epidemiology, pathogen genomes, and bioinformatics for the prevention and control of microbial threats to public health.In March 2022, the National Institutes of Health (NIH) allocated $89 million in funding for advancing genome editing projects to develop new technologies and novel research approaches in the somatic cell genome editing program.According to the UK Parliament article published in December 2022, the U.K. government provided $27 million (£22 million) in funding to Genomics England for sequencing 15,000 to 25,000 participants from diverse backgrounds by 2025 and tackling health inequalities in genomic medicine.
Automation in Next-Generation Sequencing (NGS): A Key Trend in the Genomics Market
The ability to sequence the genes of any organism for clinical and research purposes has proved to be a game changer for public health. Portable handheld sequencing devices are paving the way for the growth of the genomics market, making sequencing cheaper, simpler, and faster without the need for large clinical laboratories. Real-time sequencing has enabled researchers and physicians to quickly access sequencing data and act instantly. Portable nanopore-based sequencers can sequence the entire genome in less than $1,000. Additionally, automating NGS library preparation has helped researchers improve their library quality and achieve consistent yields, enabling the generation of reliable and reproducible NGS data.
NGS automation has also enhanced the efficiency of sequencing in terms of time and cost. The risk of contamination is greatly decreased by reducing human interactions with reagents and samples. According to a study that analyzed the cost breakdown for genome sequencing, lab personnel account for around 15% of the total cost of sequencing in a conventional clinical laboratory. A similar study showed that when an automated system is used for sample preparation, the cost of laboratory personnel decreases to around 4% of the total cost. Thus, automation optimizes & streamlines NGS workflows.
Explore the Key Market Segments Driving Growth (Download Free Sample) – https://www.meticulousresearch.com/download-sample-report/cp_id=1262
Genomics Market Analysis: Key Segmental Findings
By offering: In 2024, the consumables segment is expected to account for the largest share of 68.9% of the genomics market. The segment’s large market share can be attributed to the increasing demand for consumables due to the growing number of genomic tests, more recurring purchases of consumables compared to instruments, and the increasing prevalence of genetic diseases. For instance, according to a report published by MJH Life Sciences (U.S.) in 2022, approximately 300,000 babies are born with sickle cell disease per year globally, and nearly 5% of the world’s population is affected by the disease.By Technology: In 2024, the sequencing segment is expected to register the highest CAGR of 15.3% during the forecast period 2024–2031. The high growth of this segment is driven by the growing adoption of NGS for sequencing, the rising prevalence of cancer & the expanding application of NGS in cancer treatment & research, the declining costs of NGS, and technological advancements in NGS. Additionally, the growing demand for NGS automation, and the development of portable sequencing technologies also support the growth of this segment.
Geographic Analysis:
North America Poised to Dominate the Genomics Market in 2024
Based on geography, the genomics market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. In terms of value, in 2024, North America is expected to account for the largest share of 53.3% of the genomics market. This market is projected to reach $36.2 billion by 2031. North America’s dominant position in the genomics market is attributed to government initiatives toward the development of genomic medicine, the increased use of genomics since the COVID-19 pandemic, increasing research in the field of genomics, and the advanced healthcare infrastructure in the region.
Have specific research needs? Request a customized research report – https://www.meticulousresearch.com/request-customization/cp_id=1262
In addition, North America is home to numerous renowned research institutions, universities, and organizations dedicated to genomics research—examples include the Broad Institute, Harvard University, MIT, and the National Institutes of Health (NIH) in the U.S., as well as the University of Toronto, McGill University, and the Ontario Institute for Cancer Research (OICR) in Canada. In North America, genomics is a multidisciplinary field encompassing research, technology development, and applications related to the study of genomes (complete sets of genes within an organism’s DNA). In North America, genomics has been a significant and rapidly evolving field with broad applications in various areas of science and medicine.
In 2024, the U.S. is expected to account for the dominant share of 91.6% of the genomics market in North America. The country’s large market share is mainly attributed to the availability of advanced technologies & resources for healthcare, research funding, government initiatives to promote precision medicine, high public & private investments in genomics, and the availability of skilled professionals in the country.
Asia-Pacific: The Fastest-growing Regional Market
The genomics market in Asia-Pacific is projected to register the highest CAGR of 13.8% during the forecast period. In 2024, China is expected to account for the largest share of 38.9% of the genomics market in Asia-Pacific. Economic growth in many Asia-Pacific countries has increased government focus on the healthcare sector in terms of investments aimed at improving access to healthcare facilities and building better healthcare infrastructure. Rapid urbanization, the need to manage the growing burden of infectious diseases, efforts to improve access to diagnostic services, and rising awareness regarding health and treatment availability are driving the growth of this market. Moreover, rising middle-class populations and their disposable incomes, increasing health insurance penetration, the growing potential of personalized therapies, and public and private investments are expected to support market growth during the forecast period.
Funding from public & private organizations for the development of innovative genomic medicine has increased China’s focus on strengthening its genomics market.
Some of the recent key developments in this market are as follows:
In January 2023, Qitan Technology Co. Ltd. (China) raised $104 million (¥700 million) in a series C round to improve its nanopore sequencing devices and expand its market in China.In June 2022, Chinese sequencing technology company Axbio secured $100 million in Series B funding. The funds supported the development and commercialization of its nanopore-based sequencer and the building of a manufacturing facility.In 2016, the People’s Republic of China announced $9 billion in funding for a 15-year project to collect, analyze, and sequence genomic data and become a global leader in precision medicine.
Need Insights on Regional Data? Check Out Our Detailed Analysis (Download Free Sample) –
Genomics Market: Competition Analysis
This report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, and key growth strategies adopted over the past 3–4 years. Major companies in the genomics market have implemented various strategies to expand their product offerings and global footprints and augment their market shares. The key strategies followed by most companies in the genomics market include product launches, expansions, agreements, collaborations, and partnerships. The key players operating in the genomics market include Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Eppendorf SE (Germany), Myriad Genetics, Inc. (U.S.), Revvity, Inc. (Formerly PerkinElmer, Inc.) (U.S.), and BGI Genomics Co. Ltd (China).
The report includes a competitive dashboard that summarizes the market positions of the 20 profiled market players in four quadrants, namely Industry Leaders, Differentiators, Emerging Companies, and Vanguards. These companies are positioned based on various parameters, including revenue, depth of offerings, brand equity, geographic presence, innovation, and organic & inorganic growth strategies. Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V (U.S.), and Danaher Corporation (U.S.) were positioned in the Industry Leaders quadrant.
Learn About the Top Companies Influencing Market Dynamics (Download Free Sample) –
Genomics Industry Overview: Latest Strategic Developments from Key Industry Players
In January 2024, Thermo Fisher Scientific Inc. (U.S.) received GMP approval from the Italian Medicines Agency (AIFA) for its manufacturing facility for RNA-based products in Monza, Italy.In January 2024, Thermo Fisher launched the Axiom PangenomiX Array, a comprehensive and ethnically diverse genomic coverage on a high-throughput microarray that delivers multi-disease and pharmacogenomic research analysis across global populations.In January 2024, Illumina, Inc. (U.S.) extended its collaboration with Janssen Research & Development, LLC (U.S.) for the development of Illumina’s novel Molecular Residual Disease (MRD) assay, a Whole-genome Sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA (ctDNA).In January 2024, QIAGEN N.V. (Netherlands) announced plans to open its regional headquarters in Riyadh, Saudi Arabia, to further strengthen its footprint in the region. QIAGEN had also signed a Memorandum of Understanding (MoU) with Saudi Arabia’s Ministry of Health, addressing various public health and infection control initiatives.In December 2023, Danaher Corporation (U.S.) acquired Abcam plc (U.K.). Abcam operates as a standalone company and brand within Danaher’s Life Sciences segment, furthering Danaher’s strategy to help map complex diseases and accelerate drug discovery.In September 2023, Integrated DNA Technologies, a subsidiary of Danaher Corporation (U.S.), launched xGen NGS products designed exclusively for the Ultima Genomics UG 100TM platform.In June 2023, Agilent Technologies, Inc. (U.S.) launched Agilent 6495D LC/TQ and Agilent Revident LC/Q-TOF. The company also launched Agilent MassHunter Explorer Profiling software and the new Agilent ChemVista library manager software.In May 2022, Bio-Rad Laboratories, Inc. (U.S.) launched the CFX Duet Real-Time PCR System to support researchers in developing singleplex and duplex quantitative PCR (qPCR) assays.In December 2021, Pacific Biosciences of California, Inc. (U.S.) launched its HiFiViral SARS-CoV-2 Kit, which helps detect the Omicron Variant and provides information important for public health.
IMMEDIATE DELIVERY AVAILABLE | BUY THIS RESEARCH REPORT (Insights, Charts, Tables, Figures and More) – https://www.meticulousresearch.com/Checkout/61289368
Scope of the Report:
Genomics Market Assessment—by Offering
ConsumablesInstrumentsSoftwareServices
Genomics Market Assessment—by Technology
Polymerase Chain Reaction (PCR)SequencingNext-generation Sequencing (NGS)Other Sequencing TechnologiesNucleic Acid Extraction & PurificationMicroarrayOther Technologies
Note: Other sequencing technologies include pyrosequencing, degradome sequencing, Sanger sequencing, Chromatin Immunoprecipitation (ChIP) sequencing, and methylation sequencing.
Note: (Other technologies include cell counting, transfection, and gene editing.)
Click Here For More Details – https://www.meticulousresearch.com/download-sample-report/cp_id=1262
Genomics Market Assessment—by Application
DiagnosticsDrug Discovery & DevelopmentLife Sciences ResearchCancer ResearchStem Cell ResearchOther Life Sciences ResearchOther Applications
Note: Other life sciences research applications include cardiovascular diseases, osteoporosis, immunology, neurobiology, cellular & molecular biology, and diabetes research.
Note: Other applications include agriculture, forensics, and environmental applications.
Genomics Market Assessment—by End User
Pharmaceutical & Biotechnology CompaniesHospitals & ClinicsDiagnostics LaboratoriesContract Research Organizations (CROs)Academic & Research InstitutesOther End Users
Note: Other end users include food & beverage companies, agricultural companies, and forensics.
Browse In-depth Report Now – https://www.meticulousresearch.com/product/genomics-market-1262
Genomics Market Assessment—by Geography
North AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalySpainRest of EuropeAsia-PacificChinaJapanIndiaRest of Asia-PacificLatin AmericaBrazilMexicoRest of Latin AmericaMiddle East & Africa
Browse More Related Reports –
Animal Genetics Market is projected to hit $9.12 billion by 2031, growing at a CAGR of 5.8% from 2024. Discover key trends driving this growth – https://www.meticulousresearch.com/product/animal-genetics-market-5863
Spatial Genomics & Transcriptomics Market is projected to reach $3.23 billion by 2031 at a CAGR of 27.8% from 2024 to 2031 – https://www.meticulousresearch.com/product/spatial-genomics-market-5763
According to this latest publication from Meticulous Research,genetic testing market is projected to reach $ 28.24 billion by 2030, at a CAGR of 10.4% – https://www.meticulousresearch.com/product/genetic-testing-market-5370
Global Artificial Intelligence in genomics market is slated to register a CAGR of 42.8% during forecast period 2022–2029 to reach $6.22 billion by 2029 – https://www.meticulousresearch.com/product/ai-in-genomics-market-5345
Next Generation Sequencing For Industry Outlook is projected to reach $42.7 billion by 2031 at a CAGR of 15.7% from 2024 to 2031 – https://www.meticulousresearch.com/product/NGS-market-industry-outlook-5957
NGS Automation Market is expected to grow at a CAGR of 13.4% from 2022–2029 to reach $1.33 billion by 2029 – https://www.meticulousresearch.com/product/ngs-automation-market-5271
Saudi Arabia’s NGS market, valued at $24.4 Million in 2023, is projected to grow to $50 Million by 2031, with a CAGR of 10.1% from 2024 to 2031 – https://www.meticulousresearch.com/product/saudi-arabia-ngs-market-6002
Latin America NGS Market is expected to register a CAGR of 13.9% from 2024 to 2031 to reach $765.2 million by 2031 – https://www.meticulousresearch.com/product/latin-america-ngs-market-5780
Asia-Pacific Next Generation Sequencing (NGS) Market is expected to grow at a CAGR of 16.9% from 2024 to 2030 to reach $6.38 billion by 2030 – https://www.meticulousresearch.com/product/asia-pacific-next-generation-sequencing-market-5722
North America NGS Market to be worth $13.7 billion by 2030, growing at a 16% CAGR from 2024–2030 – https://www.meticulousresearch.com/product/north-america-ngs-market-5607
Genomics Market Report Summary:
Particulars
Details
Number of Pages
320
Format
Forecast Period
2024-2031
Base Year
2023
CAGR (2024–2031)
11.1 %
Estimated Market Size (Value)
$70.52 Billion by 2031
Segments Covered
By Offering
InstrumentsConsumablesSoftwareServices
By Technology
Polymerase Chain Reaction (PCR)SequencingNGSOther Sequencing TechnologiesNucleic Acid Extraction and PurificationMicroarrayOther Technologies
(Note 1: Other sequencing technologies include pyrosequencing, degradome sequencing, Sanger sequencing, Chromatin Immunoprecipitation (ChIP) sequencing, and methylation sequencing.
Note 2: Other technologies include cell counting, transfection, and gene editing.)
By Application
DiagnosticsDrug Discovery & DevelopmentLife Science ResearchCancer ResearchStem Cell ResearchOther Life Science ResearchOther Applications
(Note 1: Other life science research applications include cardiovascular diseases, osteoporosis, immunology, neurobiology, cellular and molecular biology, and diabetes research.
Note 2: Other applications include agriculture, forensics, and environmental applications.)
By End User
Pharmaceutical & Biotechnology CompaniesHospitals & ClinicsDiagnostics LaboratoriesContract Research Organizations (CROs)Academic & Research InstitutesOther End Users
(Note: Other end users include food & beverage companies, agricultural companies, and forensics.)
Countries Covered
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and the Middle East & Africa
Key Companies Profiled
Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Eppendorf SE (Germany), Myriad Genetics, Inc. (U.S.), Revvity, Inc. (Formerly PerkinElmer, Inc.) (U.S.), and BGI Genomics Co. Ltd (China)
Click here to: Get Free Sample Pages of this Report
Hot Industry Reports: Emerging Trends and Market Forecasts –
Automated Material Handling Systems Market Size, Share, & Report 2030 – https://www.meticulousresearch.com/product/automated-material-handling-systems-market-5149
Healthcare Cybersecurity Market Size, Share, & Report 2031 – https://www.meticulousresearch.com/product/healthcare-cybersecurity-market-5116
Direct to Consumer (DTC) Pet Food Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/direct-to-consumer-pet-food-market-5146
Haematococcus Pluvialis Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/haematococcus-pluvialis-market-5142
South East Asia English Language Learning Market by Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/south-east-asia-english-language-learning-market-5677
Interactive Display Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/interactive-display-market-5125
Semiconductor and Circuit Manufacturing Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/semiconductor-and-circuit-manufacturing-market-5092
Automotive Powertrain Sensors Market Trends & Forecast – https://www.meticulousresearch.com/product/automotive-powertrain-sensors-market-5155
Water Quality Testing Market Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/water-quality-testing-market-5501
Clear Aligners Market Size, Share & Trends: 2023 to 2030 – https://www.meticulousresearch.com/product/clear-aligners-market-5331
Testing, Inspection and Certification Market 2030 Key Trends – https://www.meticulousresearch.com/product/testing-inspection-and-certification-market-5151
Power Tools Market: Size, Share, Trends, & Forecast Analysis – https://www.meticulousresearch.com/product/power-tools-market-5810
Medical Laser Market Growth & Share Insights 2024 – 2031 – https://www.meticulousresearch.com/product/medical-lasers-market-5196
Laser Technology Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/laser-technology-market-5189
Dialysis Market Size, Share, Growth, & Trends Report 2031 – https://www.meticulousresearch.com/product/dialysis-market-5137
Tertiary Water and Wastewater Treatment Technologies Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/tertiary-water-and-wastewater-treatment-technologies-market-5185
Parking Management Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/parking-management-market-5094
Dunaliella Salina Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/dunaliella-salina-market-5168
Electric Car Market: Power Trends & Forecasts 2024 – https://www.meticulousresearch.com/product/electric-car-market-5187
Pharmaceutical Contract Development and Manufacturing Market – https://www.meticulousresearch.com/product/pharmaceutical-contract-development-and-manufacturing-market-5171
Delivery Drones Market: Trends, Size & Forecasts to 2031 – https://www.meticulousresearch.com/product/delivery-drones-market-5193
Electric Vehicle Market Trends & Forecast Analysis – https://www.meticulousresearch.com/product/electric-vehicle-market-5179
IoT Sensors Market Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/iot-sensors-market-5738
Virtualized Evolved Packet Core Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/virtualized-evolved-packet-core-market-5201
Seaweed Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/seaweed-market-5183
Dental 3D Printing Material Market Size, Share, Growth, & Trends – https://www.meticulousresearch.com/product/dental-3d-printing-material-market-5204
SCADA Market Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/scada-market-5186
IoT Security Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/iot-security-market-5254
Electric Scooter Market Size, Share, Report, & Trends 2031 – https://www.meticulousresearch.com/product/electric-scooter-market-5191
Canada Black Soldier Fly Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/canada-black-soldier-fly-market-5230
Contact:
Mr. Khushal Bombe
Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe: +44-203-868-8738
APAC: +91 744-7780008
Email- mailto:sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Meticulousblog.org | Top Market Research Reports Blog – https://meticulousblog.org/
Content Source: https://www.meticulousresearch.com/pressrelease/245/genomics-market
Photo: https://mma.prnewswire.com/media/2514303/Genomics_Market_Size.jpg
Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/genomics-market-to-reach-70-52-billion-by-2031–driven-by-increasing-incorporation-of-genomic-data-in-clinical-workflows-and-increasing-funding-and-investments-in-genomics-projects—exclusive-report-by-meticulous-research-302257383.html
SOURCE Meticulous Market Research Pvt. Ltd.
You may like
Technology
UPM Half Year Financial Report 2026: Improved second quarter results in all businesses and portfolio change progressing
Published
3 minutes agoon
July 23, 2026By
UPM-Kymmene Corporation Stock Exchange Release (Half Year Financial Report) July 23, 2026 at 09:30 EEST
HELSINKI, July 23, 2026 /PRNewswire/ —
UPM Half Year Financial Report 2026:
Improved second quarter results in all businesses and portfolio change progressing
Q2 2026 highlights, continuing operations
Sales totaled €2,355 million (2,341 million in Q2 2025)Comparable EBIT increased by 71% to €212 million, 9.0% of sales (124 million, 5.3%)All businesses improved their results from last yearUPM and Sappi signed a definitive agreement on the graphic paper Joint VentureThe Board approved a plan to demerge the Plywood business into a new listed company. The Extraordinary General Meeting to decide on the demerger plan will be held on August 31, 2026UPM achieved a Platinum rating from EcoVadis and an A score from CDP for its supplier engagement
H1 2026 highlights, continuing operations
Sales totaled €4,781 million (4,914 million in H1 2025)Comparable EBIT increased by 17% to €471 million, 9.8 % of sales (404 million, 8.2 %)Strong performance in Decarbonization solutions businesses (UPM Energy and UPM Biofuels)Robust sales growth and performance in Advanced materials businesses (UPM Adhesive Materials and UPM Specialty Materials)Operating cash flow was €225 million (468 million)1)The first installment of the dividend for the year 2025 was paid in April, totaling €395 millionNet debt was 3,313€ million at the end of June (3,310 million) and net debt to EBITDA ratio was 2.36 (2.12)1)
1) Operating cash, net debt and net debt to EBITDA ratio include continuing and discontinued operations.
UPM Plywood is presented as discontinued operations due to the proposed demerger
On April 29, 2026, the Board of Directors of UPM approved a demerger plan for the separation of the Plywood business into an independent listed company. As a result of the proposed demerger, the Plywood business is presented as a discontinued operation in accordance with IFRS 5. Unless otherwise stated, the commentary in this report relates to UPM’s continuing operations. More information in Financial statement information Note 10 assets and liabilities classified as held for distribution to owners and discontinued operations.
Key figures, continuing operations
Q2/2026
Q2/2025
Q1/2026
Q1-Q2/2026
Q1-Q2/2025
Q1-Q4/2025
Sales, € million
2,355
2,341
2,425
4,781
4,914
9,392
Comparable EBITDA, € million
356
250
375
732
659
1,254
% of sales
15.1
10.7
15.5
15.3
13.4
13.4
Operating profit (loss), € million
208
105
245
453
296
719
Comparable EBIT, € million
212
124
259
471
404
883
% of sales
9.0
5.3
10.7
9.8
8.2
9.4
Profit (loss) before tax, € million
182
83
226
409
249
660
Comparable profit before tax, € million
186
103
240
426
359
825
Profit (loss) for the period, € million
163
70
195
358
208
466
Comparable profit for the period, € million
163
87
203
366
305
684
Earnings per share (EPS), €
0.29
0.13
0.36
0.65
0.38
0.86
Comparable EPS, €
0.29
0.16
0.38
0.67
0.56
1.27
Return on capital employed (ROCE), %
5.9
3.2
7.2
6.6
4.2
5.4
Comparable ROCE, %
6.0
3.7
7.6
6.9
5.7
6.5
Capital employed at the end of period, € million
13,954
14,213
14,186
13,954
14,213
13,948
Personnel at the end of period
13,665
14,764
13,347
13,665
14,764
13,676
UPM presents certain measures of performance, financial position and cash flows, which are alternative performance measures in accordance with the guidance issued by the European Securities and Markets Authority (ESMA). The definitions of alternative performance measures are presented in UPM’s » Annual Report 2025
Key figures, discontinued operations
The financial information presented for the discontinued operations is not representative of the historical or future profitability of the UPM Plywood business area as a standalone business. Information on UPM Plywood’s performance is presented in the segment information.
Q2/2026
Q2/2025
Q1/2026
Q1-Q2/2026
Q1-Q2/2025
Q1-Q4/2025
Sales, € million
84
59
80
164
132
264
Comparable EBITDA, € million
20
7
20
39
19
57
% of sales
23.3
11.9
24.8
24.0
14.8
21.5
Operating profit (loss), € million
9
2
10
20
9
30
Comparable EBIT, € million
18
2
15
33
9
38
% of sales
21.4
3.2
19.0
20.2
6.9
14.4
Profit (loss) before tax, € million
4
2
10
14
9
30
Comparable profit before tax, € million
18
2
15
33
9
38
Profit (loss) for the period, € million
3
1
5
9
7
24
Comparable profit for the period, € million
14
1
9
24
7
31
Return on capital employed (ROCE), %
21.7
3.9
22.0
21.9
9.8
16.4
Comparable ROCE, %
37.4
4.3
32.7
35.1
10.0
20.8
Capital employed at the end of period, € million
196
181
189
196
181
181
Personnel at the end of period
1,519
1,543
1,454
1,519
1,543
1,451
Key figures, UPM total
UPM total
Q2/2026
Q2/2025
Q1/2026
Q1-Q2/2026
Q1-Q2/2025
Q1-Q4/2025
Sales, € million
2,440
2,400
2,505
4,945
5,046
9,656
Comparable EBITDA, € million
376
257
395
771
678
1,311
% of sales
15.4
10.7
15.8
15.6
13.4
13.6
Operating profit (loss), € million
217
107
255
472
305
749
Comparable EBIT, € million
230
126
274
504
413
921
% of sales
9.4
5.2
10.9
10.2
8.2
9.5
Profit (loss) before tax, € million
186
85
236
422
258
690
Comparable profit before tax, € million
204
105
255
459
367
863
Profit (loss) for the period, € million
166
71
200
366
215
491
Comparable profit for the period, € million
177
89
213
390
312
714
Earnings per share (EPS), €
0.30
0.13
0.37
0.67
0.39
0.91
Comparable EPS, €
0.32
0.17
0.39
0.71
0.57
1.33
Return on equity (ROE), %
6.4
2.7
7.6
7.1
3.9
4.5
Comparable ROE, %
6.8
3.4
8.1
7.6
5.7
6.5
Return on capital employed (ROCE), %
6.1
3.2
7.4
6.8
4.3
5.5
Comparable ROCE, %
6.5
3.7
7.9
7.2
5.8
6.7
Operating cash flow, € million
136
179
89
225
468
1,405
Operating cash flow per share, €
0.26
0.34
0.17
0.43
0.88
2.66
Equity per share at the end of period, €
18.86
18.96
19.48
18.86
18.96
18.97
Capital employed at the end of period, € million
14,149
14,394
14,375
14,149
14,394
14,129
Net debt at the end of period, € million
3,313
3,310
2,962
3,313
3,310
3,004
Net debt to EBITDA (last 12 months)
2.36
2.12
2.30
2.36
2.12
2.29
Personnel at the end of period
15,184
16,307
14,801
15,184
16,307
15,127
Massimo Reynaudo, President and CEO, comments on the results:
“In the second quarter, we reached two important milestones in the transformation of UPM. We signed the definitive agreement to create the graphic paper joint venture with Sappi, and advanced the separation of the plywood business into the future WISA Group. Following these steps, UPM is positioned with stronger growth prospects and improved earnings quality.
During the quarter, all our businesses improved their results compared to the same period last year, with most also outperforming the previous quarter. Increased volumes, margin management and sustained efficiency measures supported our profitability in a business environment that turned inflationary.
In Q2, sales from our continuing operations were slightly up at €2,355 million, and comparable EBIT increased to €212 million, 71 percent higher than in the same period last year. Net debt at the end of the reporting period was €3,313 million, including both continuing and discontinued operations, and net debt to EBITDA ratio was 2.36.
In decarbonization solutions, UPM Biofuels recorded a strong quarter with good demand and healthy bio-premiums for advanced renewable fuels. Prices were further supported by higher fossil fuel reference prices. The ramp-up of our biorefinery in Leuna, Germany, continued. Customer deliveries of industrial sugars reached substantial volumes, and deliveries of renewable functional fillers and other lignin derivatives are expected to start during Q3. UPM Energy improved its results from last year, although the second quarter saw normal seasonality. Structurally, electricity consumption continued to grow year-on-year, and we are well positioned to create value by serving new large-scale consumers.
The markets for our advanced materials businesses, UPM Adhesive Materials and UPM Specialty Materials, showed robust growth in Europe and Asia. Both businesses succeeded in the markets, thanks to a focus on commercial excellence and product portfolio development, and sharpened competitiveness.
Our world-class pulp platform in Uruguay, UPM Fibres South, has consistently improved efficiency for several quarters in a row. In the second quarter, this helped us to fully offset the increases in logistics and other costs. Profitability was further improved by a moderate increase in pulp prices.
For the Fibres North platform in Finland, the business environment is challenging. Even though pulpwood prices have decreased, profitability remains low. The second quarter earnings were also impacted by the maintenance shutdown at the UPM Pietarsaari mill. We are planning temporary shutdowns of the UPM Kaukas pulp mill and potentially the UPM Pietarsaari pulp mill, to optimize production and wood sourcing, and ensure profitability.
UPM Communication Papers’ business performance was broadly stable, with slightly improved margins. Preparations for the planned graphic paper Joint Venture continued. In late May we signed the definitive agreement with Sappi, and secured financing arrangements for the Joint Venture. The EU merger control process moved to Phase II, with final resolutions expected by the end of 2026.
UPM Plywood continued to perform well as the business prepared for separation into an independent listed company, WISA Group. In April, the Board of Directors approved the demerger plan. Subject to the decision of the Extraordinary General Meeting, trading in the shares of WISA Group on Nasdaq Helsinki is currently expected to commence in early November. By separating the plywood business onto its own growth path, we are strengthening its future prospects and streamlining UPM’s business portfolio.
Following the planned graphic paper joint venture and plywood separation, UPM operates in structurally growing markets. The ongoing reshaping of UPM’s portfolio highlights our position in businesses with stronger growth characteristics, and our direction going forward is towards higher value-added products and lower cyclicality.”
Profit guidance, continuing operations
UPM’s comparable EBIT in H2 2026 from continuing operations is expected to be approximately in the range of €375-575 million (€479 million in H2 2025, and €471 million in H1 2026). These figures exclude UPM Plywood, which is classified as discontinued operations.
Outlook
There continue to be significant uncertainties in geopolitics and trade.
In H2 2026, compared with H1 2026, UPM’s performance is expected to be supported by moderately higher sales prices. Variable costs are expected to increase moderately. Energy refunds are expected to support UPM Communication Papers’ result in Q4. Maintenance activity is expected to increase from the comparison period. The production ramp-up at UPM Leuna is expected to increase costs.
In H2 2026, compared with H2 2025, UPM’s performance is expected to benefit from higher sales prices. Variable costs are expected to increase moderately. Fair value change of forest assets is expected to have a significantly smaller impact on comparable EBIT in H2 2026 than in H2 2025 (€131 million). The energy refunds to be booked in UPM Communication Papers in Q4 are anticipated to have a somewhat smaller positive impact than in 2025. Maintenance activity is expected to increase from the comparison period. The production ramp-up at UPM Leuna is expected to increase costs.
Sensitivity to pulp and electricity prices
UPM’s comparable EBIT is sensitive to pulp and electricity prices. The figures below represent group earnings sensitivities on annual level.
UPM is a large producer and consumer of chemical pulp. A €50/tonne change in average pulp price would impact annual comparable EBIT by approximately €180 million (net impact: assuming no correlation between pulp and paper prices) to approximately €270 million (gross impact: assuming paper pricing would match changes in pulp costs).
UPM is a large producer and consumer of electricity in Finland and separately hedges part of its electricity sales and purchases. Based on UPM’s estimated unhedged net electricity sales position in Finland in 2026, a €10/MWh change in average electricity market price in Finland would impact annual comparable EBIT by approximately €40 million.
Foreign exchange exposure
Fluctuations in monetary policies and economic conditions can significantly impact the value of various currencies, which in turn may affect UPM. Additionally, the escalation of global trade tensions could influence currency exchange rates. These currency fluctuations could impact UPM’s cash flow, earnings, or balance sheet, and may also affect the relative competitiveness between different currency regions.
The Group’s policy is to hedge an average of 50% of its estimated net currency cash flows on a rolling basis over the next 12-month period. At the end of Q2 2026, UPM’s estimated net currency cash flows for the next 12 months totaled approximately €1.5 billion. USD was the largest exposure at approximately €1.4 billion, followed by UYU, GBP, CNY and JPY. In addition, the earnings of UPM’s foreign subsidiaries are translated to euros in reporting. UPM has significant foreign subsidiaries in Uruguay, the U.S. and China. Foreign exchange risks are discussed in UPM’s Annual Report 2025 on pages 313-314.
Invitation to UPM’s webcast on the half-year financial report 2026
A webcast and a conference call for analysts and investors will start at 13:15 EEST. The 2026 half-year financial report will be presented in English by President and CEO Massimo Reynaudo and CFO Tapio Korpeinen. Participants can follow the webcast online via this link.
Participants wishing to ask questions after the presentation must register for the conference call. To participate in the conference call, please register here. After registering, you will be provided with telephone numbers, a user ID and a conference ID to access the conference. To ask a question, press *5 on your telephone keypad to join the queue.
The webcast will be available on the company website for 12 months after the call.
*
It should be noted that certain statements herein, which are not historical facts, including, without limitation, those regarding expectations for market growth and developments; expectations for growth and profitability; and statements preceded by “believes”, “expects”, “anticipates”, “foresees”, or similar expressions, are forward-looking statements. Since these statements are based on current plans, estimates and projections, they involve risks and uncertainties which may cause actual results to materially differ from those expressed in such forward-looking statements. Such factors include, but are not limited to: (1) operating factors such as continued success of manufacturing activities and the achievement of efficiencies therein including the availability and cost of production inputs, continued success of product development, acceptance of new products or services by the Group’s targeted customers, success of the existing and future collaboration arrangements, changes in business strategy or development plans or targets, changes in the degree of protection created by the Group’s patents and other intellectual property rights, the availability of capital on acceptable terms; (2) industry conditions, such as strength of product demand, intensity of competition, prevailing and future global market prices for the Group’s products and the pricing pressures thereto, financial condition of the customers and the competitors of the Group, the potential introduction of competing products and technologies by competitors; and (3) general economic conditions, such as rates of economic growth in the Group’s principal geographic markets or fluctuations in exchange and interest rates. The main earnings sensitivities and the group’s cost structure are presented on page 276 of the Annual Report 2025. Risks and opportunities are discussed on pages 31-33, and risks and risk management are presented on pages 128-132.
UPM, Media relations
Mon-Fri 9:00-16:00 EEST
tel. +358 40 588 3284
media@upm.com
UPM
UPM is a material solutions company, renewing products and entire value chains with an extensive portfolio of renewable fibres, advanced materials, decarbonization solutions, and communication papers. Our performance in sustainability has been recognized by third parties, including EcoVadis and the Dow Jones Sustainability Indices. We operate globally and employ approximately 15,100 people worldwide, with annual sales of approximately €9.7 billion. Our shares are listed on Nasdaq Helsinki Ltd.
UPM – we renew the everyday
Read more: upm.com
Follow us on LinkedIn | YouTube | Instagram | #UPM #materialsolutions #WeRenewTheEveryday
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/23100/4377000/4201405.pdf
UPM-Half-Year-Financial-Report-2026-en
View original content:https://www.prnewswire.co.uk/news-releases/upm-half-year-financial-report-2026-improved-second-quarter-results-in-all-businesses-and-portfolio-change-progressing-302833082.html
Technology
Acrab Unveils GΞLIX 1 SoC and Agent Box, Bringing State-of-the-Art AI to the Edge
Published
3 minutes agoon
July 23, 2026By
Built on a 5-nanometer process, the new SoC is designed to support models in the 100 billion parameter class, with full-stack software for private and responsive AI agents at the edge
SINGAPORE, July 23, 2026 /PRNewswire/ — Acrab, a technology company building agentic AI compute infrastructure for the next generation of intelligent systems, today unveiled GΞLIX 1, its first-generation edge AI system-on-chip (SoC), together with Agent Box, a personal edge AI system powered by the company’s full-stack computing platform.
As AI moves from generating answers to completing tasks, agents increasingly need to understand context, remember preferences and coordinate tools and devices in real time. Running these capabilities locally can produce faster responses, keep sensitive information under the user’s control and maintain core functions when cloud connectivity is limited.
For years, models in the 100 billion parameter class have required cloud infrastructure. GΞLIX 1 is designed to bring state-of-the-art AI models at this scale into locally operated edge systems. Powered by GΞLIX, Acrab’s Agent Box is a high-performance personal edge AI center designed to put AI agents into action in a more personal and customized way, with local large model inference, persistent memory, multimodal interactions and agent orchestration capabilities.
By replacing cloud AI’s recurring token-fees per use, Agent Box is a one-time investment with long-term value, hence relieving users’ token anxiety, and allowing AI to move from an occasional tool into an always-available assistant woven into everyday work and life.
“Generative AI helped people find answers. Agentic AI will help them get things done,” said Dr. Ken Phua, CEO of Acrab. “Running models in the 100 billion parameter class on a system small enough to sit on a desk presents a significant computing challenge. GΞLIX 1 is designed to deliver the performance, memory bandwidth and responsive local inference required, while Agent Box shows how that capability can become a complete user experience.”
A private AI center built for everyday life
Agent Box is designed as a private, always-on AI center for personal workspaces and homes. It keeps intelligence close to the people, information and physical environments it serves, while showing how device makers can turn Acrab’s computing platform into complete agentic AI experiences.
For decades, personal computing advanced in predictable steps: faster processors, larger screens, more storage. Agent Box represents something else entirely—the first system designed not to run programs, but to host intelligence.
Agent Box brings together local language and vision model inference, multimodal interaction, persistent memory and an orchestration layer that can understand goals, break tasks into steps and coordinate action across agents, systems and connected devices. Users’ data and memories remain private and stored locally on the device, while the system grows more capable and customized as the context deepens and memories accumulate. Acrab designed the compute architecture from the ground up to achieve optimal local AI performance, usability, cost efficiency, and power efficiency within one device.
A purpose-designed SoC for large model inference at the edge
GΞLIX 1 is built on a 5-nanometer process and is Acrab’s first SoC designed specifically for edge AI. Rather than relying on separate compute components, it integrates CPU, GPU and NPU resources with a unified memory architecture engineered for large AI models and agentic workloads.
The SoC features a 20-core Arm CPU, multicore NPU acceleration and 273 GB/s of unified memory bandwidth. It is designed to support local deployment of open-source models in up to the 100 billion parameter class, with coordinated execution across CPU, GPU and NPU resources. Supporting models at this scale locally places substantial demands on computing performance, memory bandwidth and power efficiency.
GΞLIX 1 is engineered for rapid responses at power levels suitable for systems that remain active throughout the day. A central design goal was reducing the delay before a model begins to respond, particularly with long prompts and large context windows.
In company testing, GΞLIX 1 achieved a prefill rate of 1416.8 tokens per second under a Gemma 26B A4B configuration with a 40K KV cache and a 10K token input, compared with 188.9 tokens per second on Mac Mini M4 Pro, representing up to 7.5X faster prefill performance. These capabilities turn a single chip into a versatile supercomputing platform for a wide range of applications.
A full-stack platform, from silicon to applications
Beyond the SoC, Acrab has built the software and system layers needed to turn local model inference into working agentic products. These include an optimized runtime and developer toolchain, agent operating system capabilities, reference designs and applications that help devices understand context, retain memory and coordinate real-world action.
Agent Box is the first expression of Acrab’s broader ambition to provide a horizontal computing foundation for agentic AI across a wide range of edge devices and intelligent systems.
Processing a substantial share of AI workloads locally can reduce dependence on metered cloud inference, lower recurring processing and data transfer costs, and avoid the delay involved in sending every interaction to a remote service. Cloud resources can still be used when a task requires them, allowing developers to choose the right balance between local and cloud execution.
Building a broader edge AI device ecosystem
Acrab plans to work with device manufacturers and developers to bring its computing platform into products including AI NAS systems, AI PCs, smart vehicles, and industrial and service robots.
Agent Box demonstrates how Acrab’s silicon and software can be integrated into a complete product experience. The company aims to provide a complete set of compute platform and agent-native infrastructure for the next generation of AI transformation across industries. By combining custom AI silicon, full-stack software, and reference designs of agents for use scenarios, Acrab enables industry partners and developers to bring intelligent AI products to market faster.
“Our goal is to give device makers and developers the foundation to bring agentic intelligence into many different products and environments,” Dr. Phua said. “Agent Box demonstrates what the technology can do today, while GΞLIX 1 and our full-stack platform are designed to support a much broader ecosystem of devices and applications.”
Product Launch Event Video Replay:
https://www.acrab.ai/https://www.youtube.com/watch?v=WdojjwucdTQhttps://www.linkedin.com/events/7484797078045401088/
About Acrab
Acrab is a technology company building agentic AI compute infrastructure for the next generation of intelligent systems. Founded in 2024, the company develops high-performance AI compute architecture and integrated software platforms designed to bring AI agents into action, providing personalized assistance and real-time execution across a range of edge environments.
By combining purpose-designed silicon, advanced edge AI models, full-stack software and system orchestration, Acrab provides the computing foundation for AI agent systems across everyday life, bringing assistance, creativity, utility and value.
In June 2026, Acrab announced that it had received over US$350 million in cumulative financing from global venture capital firms and strategic industry investors, including early backers Vertex Ventures Southeast Asia & India, Vertex Growth, and K3.
For more information about Acrab, please visit https://www.acrab.ai/.
View original content to download multimedia:https://www.prnewswire.com/news-releases/acrab-unveils-glix-1-soc-and-agent-box-bringing-state-of-the-art-ai-to-the-edge-302833081.html
SOURCE Acrab
Technology
IDnow Appoints Philippe Morel as Chief Executive Officer
Published
3 minutes agoon
July 23, 2026By
Philippe Morel brings over 30 years of financial services and technology leadership experience, with a track record of scaling regulated platform businesses in partnership with private equity.
MUNICH, July 23, 2026 /PRNewswire/ — IDnow, Europe’s leader in digital identity and fraud prevention, today announces the appointment of Philippe Morel as Chief Executive Officer, effective today. Philippe succeeds Andreas Bodczek, who steps down after more than seven years of leadership that transformed IDnow into a leading European provider of digital identity and fraud prevention.
The IDnow Trust Platform: From KYC to Continuous Trust
In June 2026, IDnow launched the IDnow Trust Platform, marking the company’s expansion beyond traditional identity verification. Designed to help regulated organisations move from Know Your Customer (KYC) to Trust Your Customer (TYC), the platform orchestrates identity verification, fraud prevention, biometric authentication and qualified digital trust services across the full customer lifecycle. Through four modular services — Identify, Authenticate, Protect and Trust — and its Orchestrate, Observe and Decide capabilities, customers can configure workflows, monitor risk signals in real time and automate decisions through a single integration. The platform is built to help organisations adapt to the evolving European regulatory landscape, including AMLR, eIDAS 2.0 and the emergence of EU Digital Identity Wallets, while addressing increasingly sophisticated AI-driven fraud.
A New Chapter for IDnow
Philippe Morel brings more than 30 years of leadership experience spanning financial services, technology platforms and regulated environments, with a consistent track record of strategic transformation and value creation in partnership with private equity.
Most recently, Philippe served as Chief Executive Officer of Railsr, a payments and embedded finance platform, where he led strategic repositioning and commercial rebuilding before the merger with Equals Money.
Prior to that, Philippe served as CEO of SETL, a blockchain-based financial market infrastructure provider, where he repositioned the business into payments and digital settlement networks, launched the Regulated Liability Network (RLN) tested with the New York Federal Reserve, and delivered tokenisation projects for tier-one financial institutions.
Before his executive career, Philippe worked at Boston Consulting Group, rising to Senior Partner and Managing Director. He led BCG’s Global Capital Markets practice and its Private Equity EMEA business, advising boards and CEOs of major financial institutions on strategy, transformation, M&A and growth across Europe, the US and Asia. He also served for nine years as Chair of BCG’s Global Audit and Risk Committee.
Philippe holds an MBA from Harvard Business School and a degree in Finance from HEC Paris.
Board Statement
Martin McCourt, Chair of IDnow, said: “We are delighted to welcome Philippe to IDnow at a pivotal moment. IDnow has recently launched its Trust Platform, expanding beyond traditional identity verification to help regulated organisations orchestrate identity, fraud prevention and compliance across the full customer lifecycle. Philippe’s background — combining deep strategic expertise with hands-on leadership of regulated technology and financial services platforms — is ideally suited to the opportunity ahead. We are confident that he will lead IDnow into its next phase of growth.”
Philippe Morel Statement
“IDnow is a genuinely exceptional business — a European-born leader in digital identity and fraud prevention at a moment when regulation, digital identity wallets and increasingly sophisticated fraud are reshaping the market. The newly launched IDnow Trust Platform is designed to help customers move beyond one-time verification towards continuous trust across the full customer lifecycle. I am energised by what this team has achieved and by the opportunity ahead. My first priority is to listen: to our customers, our colleagues and our partners. From there, we will define and execute IDnow’s next phase of growth together.”
A Tribute to Andreas Bodczek
The Board also takes this opportunity to express its deep gratitude to Andreas Bodczek, who has led IDnow with extraordinary vision and commitment since 2018. A seasoned technology entrepreneur with a Diplom Kaufmann from LMU München, Andreas brought to IDnow the experience of building and scaling digital businesses: as co-founder and CEO of Fyber, which he grew into a globally recognised mobile technology platform, a board partner at Point Nine Capital, and chairman at JTL Software.
At IDnow, his impact was transformative. He led the company through a pivotal transition from founder-led to PE-backed under Corsair’s ownership, providing the foundation for sustained growth. He drove the acquisitions of identity Trust Management AG and ARIADNEXT — the French market leader in remote identity verification — which significantly expanded IDnow’s capabilities, brought the Rennes engineering hub into the group, and established IDnow’s presence across Europe. Most recently, he oversaw the launch of the IDnow Trust Platform, marking the company’s expansion beyond traditional identity verification and creating a unified platform for identity, fraud prevention, authentication and qualified digital trust services across the customer lifecycle. His leadership has positioned IDnow well for its next chapter, and we wish him every success in what comes next.
About IDnow
IDnow is Europe’s leader in digital identity and fraud prevention, with a mission to transform trust into a powerful asset in the digital world. Through its broad portfolio of AI-driven, SaaS-based identity and fraud prevention solutions, IDnow establishes, maintains and enriches trust throughout the customer journey, enabling businesses to operate securely while driving growth and scalability. The IDnow Trust Platform provides unified access to identity verification, fraud prevention, biometric authentication and qualified digital trust services. IDnow has offices in Germany, the United Kingdom, Romania and France and is backed by Corsair Capital.
For more information, visit idnow.io.
View original content to download multimedia:https://www.prnewswire.com/news-releases/idnow-appoints-philippe-morel-as-chief-executive-officer-302832286.html
SOURCE IDnow
UPM Half Year Financial Report 2026: Improved second quarter results in all businesses and portfolio change progressing
Acrab Unveils GΞLIX 1 SoC and Agent Box, Bringing State-of-the-Art AI to the Edge
IDnow Appoints Philippe Morel as Chief Executive Officer
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology4 days agoEmdoor Launches “Ailyn” AI Hub at WAIC 2026: Unifying Intelligence Across Every Device
-
Coin Market4 days agoSaylor turns up heat with ‘110 reasons’ why BIP-110 is a bad idea
-
Technology5 days agoLaifen Expands U.S. Retail Footprint with Costco Launch of Best-Selling SE Hair Dryer
-
Technology5 days agoAI-Powered Connectivity: APAC Charts a Path to a Smarter Digital Future
-
Technology4 days agoPenetron Strengthens Global Research Collaboration at ICSHM 2026
-
Coin Market3 days agoWill the US get CLARITY this week? Bitcoin’s new $80K target: Hodler’s Digest, July 19
-
Technology3 days ago“Every Day CO₂ Challenge”: More Than a Game, A New Way of Learning
-
Technology5 days agoBest AI Design Tools (2026): CapCut Named a Top Choice for Creating Images and Marketing Assets by Software Experts
